Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 8 of 8 entries
Sorted by: Best Match Show Resources per page
Three New .

Food technology and biotechnology

Potočnjak M, Pušić P, Frece J, Abram M, Janković T, Gobin I.
PMID: 28559733
Food Technol Biotechnol. 2017 Mar;55(1):48-54. doi: 10.17113/ftb.55.01.17.4693.

The benefits of probiotic bacteria have been widely explored. However, fermented foods and digestive system of humans and animals are an inexhaustible source of new potentially probiotic microorganisms. In this study we present three new

Cite
Potočnjak M, Pušić P, Frece J, et al. Three New . Food Technol Biotechnol. 2017;55(1):48-54doi: 10.17113/ftb.55.01.17.4693.
Potočnjak, M., Pušić, P., Frece, J., Abram, M., Janković, T., & Gobin, I. (2017). Three New . Food technology and biotechnology, 55(1), 48-54. https://doi.org/10.17113/ftb.55.01.17.4693
Potočnjak, Mia, et al. "Three New ." Food technology and biotechnology vol. 55,1 (2017): 48-54. doi: https://doi.org/10.17113/ftb.55.01.17.4693
Potočnjak M, Pušić P, Frece J, Abram M, Janković T, Gobin I. Three New . Food Technol Biotechnol. 2017 Mar;55(1):48-54. doi: 10.17113/ftb.55.01.17.4693. PMID: 28559733; PMCID: PMC5434365.
Copy Download .nbib Format: NLM
European Network to Advance Best Practices and Technology on Medication Adherence: Mission Statement.

Frontiers in pharmacology

van Boven JF, Tsiligianni I, Potočnjak I, Mihajlović J, Dima AL, Nabergoj Makovec U, Ágh T, Kardas P, Ghiciuc CM, Petrova G, Bitterman N, Kamberi F, Culig J, Wettermark B.
PMID: 34707502
Front Pharmacol. 2021 Oct 11;12:748702. doi: 10.3389/fphar.2021.748702. eCollection 2021.

Medication non-adherence is associated with almost 200,000 deaths annually and €80-125 billion in the European Union. Novel technological advances (smart pill bottles, digital inhalers and spacers, electronic pill blisters, e-injection pens, e-Health applications, big data) could help managing non-adherence....

Cite
van Boven JF, Tsiligianni I, Potočnjak I, et al. European Network to Advance Best Practices and Technology on Medication Adherence: Mission Statement. Front Pharmacol. 2021;12:748702doi: 10.3389/fphar.2021.748702.
van Boven, J. F., Tsiligianni, I., Potočnjak, I., Mihajlović, J., Dima, A. L., Nabergoj Makovec, U., Ágh, T., Kardas, P., Ghiciuc, C. M., Petrova, G., Bitterman, N., Kamberi, F., Culig, J., & Wettermark, B. (2021). European Network to Advance Best Practices and Technology on Medication Adherence: Mission Statement. Frontiers in pharmacology, 12748702. https://doi.org/10.3389/fphar.2021.748702
van Boven, Job Fm, et al. "European Network to Advance Best Practices and Technology on Medication Adherence: Mission Statement." Frontiers in pharmacology vol. 12 (2021): 748702. doi: https://doi.org/10.3389/fphar.2021.748702
van Boven JF, Tsiligianni I, Potočnjak I, Mihajlović J, Dima AL, Nabergoj Makovec U, Ágh T, Kardas P, Ghiciuc CM, Petrova G, Bitterman N, Kamberi F, Culig J, Wettermark B. European Network to Advance Best Practices and Technology on Medication Adherence: Mission Statement. Front Pharmacol. 2021 Oct 11;12:748702. doi: 10.3389/fphar.2021.748702. eCollection 2021. PMID: 34707502; PMCID: PMC8544003.
Copy Download .nbib Format: NLM
Attitudes to Performing Clinical Trials.

Clinical therapeutics

Potocnjak I, Nham E, Degoricija V.
PMID: 27673670
Clin Ther. 2016 Oct 06;38(10):e5. doi: 10.1016/j.clinthera.2016.07.096.

No abstract available.

Cite
Potocnjak I, Nham E, Degoricija V. Attitudes to Performing Clinical Trials. Clin Ther. 2016;38(10):e5doi: 10.1016/j.clinthera.2016.07.096.
Potocnjak, I., Nham, E., & Degoricija, V. (2016). Attitudes to Performing Clinical Trials. Clinical therapeutics, 38(10), e5. https://doi.org/10.1016/j.clinthera.2016.07.096
Potocnjak, I, et al. "Attitudes to Performing Clinical Trials." Clinical therapeutics vol. 38,10 (2016): e5. doi: https://doi.org/10.1016/j.clinthera.2016.07.096
Potocnjak I, Nham E, Degoricija V. Attitudes to Performing Clinical Trials. Clin Ther. 2016 Oct 06;38(10):e5. doi: 10.1016/j.clinthera.2016.07.096. PMID: 27673670.
Copy Download .nbib Format: NLM
[Clinical aspects pathogenesis and therapy of acute poliomyelitis].

Lijecnicki vjesnik

SKRIVANELI N, ERAK P, KALAFATIC Z, POTKONJAK M.
PMID: 13234679
Lijec Vjesn. 1954;76(5):195-208.

No abstract available.

Cite
SKRIVANELI N, ERAK P, KALAFATIC Z, et al. Klinika, patogeneza i terapija akutnog stadija poliomijelitisa. [Clinical aspects pathogenesis and therapy of acute poliomyelitis]. Lijec Vjesn. 1954;76(5):195-208
SKRIVANELI, N., ERAK, P., KALAFATIC, Z., & POTKONJAK, M. (1954). Klinika, patogeneza i terapija akutnog stadija poliomijelitisa. [Clinical aspects pathogenesis and therapy of acute poliomyelitis]. Lijecnicki vjesnik, 76(5), 195-208.
SKRIVANELI, N, et al. "Klinika, patogeneza i terapija akutnog stadija poliomijelitisa." [Clinical aspects pathogenesis and therapy of acute poliomyelitis]. Lijecnicki vjesnik vol. 76,5 (1954): 195-208.
SKRIVANELI N, ERAK P, KALAFATIC Z, POTKONJAK M. Klinika, patogeneza i terapija akutnog stadija poliomijelitisa. [Clinical aspects pathogenesis and therapy of acute poliomyelitis]. Lijec Vjesn. 1954;76(5):195-208. Undetermined. PMID: 13234679.
Copy Download .nbib Format: NLM
Catalyzing Transcriptomics Research in Cardiovascular Disease: The CardioRNA COST Action CA17129.

Non-coding RNA

Gomes CPC, Ágg B, Andova A, Arslan S, Baker A, Barteková M, Beis D, Betsou F, Wettinger SB, Bugarski B, Condorelli G, Silva GJJD, Danilin S, de Gonzalo-Calvo D, Buil A, Carmo-Fonseca M, Enguita FJ, Felekkis K, Ferdinandy P, Gyöngyösi M, Hackl M, Karaduzovic-Hadziabdic K, Hellemans J, Heymans S, Hlavackova M, Hoydal MA, Jankovic A, Jusic A, Kardassis D, Kerkelä R, Kuster GM, Lakkisto P, Leszek P, Lustrek M, Maegdefessel L, Martelli F, Novella S, O'Brien T, Papaneophytou C, Pedrazzini T, Pinet F, Popescu O, Potočnjak I, Robinson E, Sasson S, Scholz M, Simionescu M, Stoll M, Varga ZV, Vinciguerra M, Xuereb A, Yilmaz MB, Emanueli C, Devaux Y, on behalf of the EU-CardioRNA COST Action (CA17129).
PMID: 30934986
Noncoding RNA. 2019 Mar 29;5(2). doi: 10.3390/ncrna5020031.

Cardiovascular disease (CVD) remains the leading cause of death worldwide and, despite continuous advances, better diagnostic and prognostic tools, as well as therapy, are needed. The human transcriptome, which is the set of all RNA produced in a cell,...

Cite
Gomes CPC, Ágg B, Andova A, et al. Catalyzing Transcriptomics Research in Cardiovascular Disease: The CardioRNA COST Action CA17129. Noncoding RNA. 2019;5(2)doi: 10.3390/ncrna5020031.
Gomes, C. P. C., Ágg, B., Andova, A., Arslan, S., Baker, A., Barteková, M., Beis, D., Betsou, F., Wettinger, S. B., Bugarski, B., Condorelli, G., Silva, G. J. J. D., Danilin, S., de Gonzalo-Calvo, D., Buil, A., Carmo-Fonseca, M., Enguita, F. J., Felekkis, K., Ferdinandy, P., Gyöngyösi, M., Hackl, M., Karaduzovic-Hadziabdic, K., Hellemans, J., Heymans, S., Hlavackova, M., Hoydal, M. A., Jankovic, A., Jusic, A., Kardassis, D., Kerkelä, R., Kuster, G. M., Lakkisto, P., Leszek, P., Lustrek, M., Maegdefessel, L., Martelli, F., Novella, S., O'Brien, T., Papaneophytou, C., Pedrazzini, T., Pinet, F., Popescu, O., Potočnjak, I., Robinson, E., Sasson, S., Scholz, M., Simionescu, M., Stoll, M., Varga, Z. V., Vinciguerra, M., Xuereb, A., Yilmaz, M. B., Emanueli, C., Devaux, Y., & on behalf of the EU-CardioRNA COST Action (CA17129). (2019). Catalyzing Transcriptomics Research in Cardiovascular Disease: The CardioRNA COST Action CA17129. Non-coding RNA, 5(2), . https://doi.org/10.3390/ncrna5020031
Gomes, Clarissa Pedrosa da C, et al. "Catalyzing Transcriptomics Research in Cardiovascular Disease: The CardioRNA COST Action CA17129." Non-coding RNA vol. 5,2 (2019). doi: https://doi.org/10.3390/ncrna5020031
Gomes CPC, Ágg B, Andova A, Arslan S, Baker A, Barteková M, Beis D, Betsou F, Wettinger SB, Bugarski B, Condorelli G, Silva GJJD, Danilin S, de Gonzalo-Calvo D, Buil A, Carmo-Fonseca M, Enguita FJ, Felekkis K, Ferdinandy P, Gyöngyösi M, Hackl M, Karaduzovic-Hadziabdic K, Hellemans J, Heymans S, Hlavackova M, Hoydal MA, Jankovic A, Jusic A, Kardassis D, Kerkelä R, Kuster GM, Lakkisto P, Leszek P, Lustrek M, Maegdefessel L, Martelli F, Novella S, O'Brien T, Papaneophytou C, Pedrazzini T, Pinet F, Popescu O, Potočnjak I, Robinson E, Sasson S, Scholz M, Simionescu M, Stoll M, Varga ZV, Vinciguerra M, Xuereb A, Yilmaz MB, Emanueli C, Devaux Y, on behalf of the EU-CardioRNA COST Action (CA17129). Catalyzing Transcriptomics Research in Cardiovascular Disease: The CardioRNA COST Action CA17129. Noncoding RNA. 2019 Mar 29;5(2). doi: 10.3390/ncrna5020031. PMID: 30934986; PMCID: PMC6630366.
Copy Download .nbib Format: NLM
Isoprene Emission Response to Drought and the Impact on Global Atmospheric Chemistry.

Atmospheric environment (Oxford, England : 1994)

Jiang X, Guenther A, Potosnak M, Geron C, Seco R, Karl T, Kim S, Gu L, Pallardy S.
PMID: 30505205
Atmos Environ (1994). 2018 Jun;183:69-83. doi: 10.1016/j.atmosenv.2018.01.026.

Biogenic isoprene emissions play a very important role in atmospheric chemistry. These emissions are strongly dependent on various environmental conditions, such as temperature, solar radiation, plant water stress, ambient ozone and CO

Cite
Jiang X, Guenther A, Potosnak M, et al. Isoprene Emission Response to Drought and the Impact on Global Atmospheric Chemistry. Atmos Environ (1994). 2018;183:69-83doi: 10.1016/j.atmosenv.2018.01.026.
Jiang, X., Guenther, A., Potosnak, M., Geron, C., Seco, R., Karl, T., Kim, S., Gu, L., & Pallardy, S. (2018). Isoprene Emission Response to Drought and the Impact on Global Atmospheric Chemistry. Atmospheric environment (Oxford, England : 1994), 18369-83. https://doi.org/10.1016/j.atmosenv.2018.01.026
Jiang, Xiaoyan, et al. "Isoprene Emission Response to Drought and the Impact on Global Atmospheric Chemistry." Atmospheric environment (Oxford, England : 1994) vol. 183 (2018): 69-83. doi: https://doi.org/10.1016/j.atmosenv.2018.01.026
Jiang X, Guenther A, Potosnak M, Geron C, Seco R, Karl T, Kim S, Gu L, Pallardy S. Isoprene Emission Response to Drought and the Impact on Global Atmospheric Chemistry. Atmos Environ (1994). 2018 Jun;183:69-83. doi: 10.1016/j.atmosenv.2018.01.026. PMID: 30505205; PMCID: PMC6260947.
Copy Download .nbib Format: NLM
A Cross-Sectional Survey on Medication Management Practices for Noncommunicable Diseases in Europe During the Second Wave of the COVID-19 Pandemic.

Frontiers in pharmacology

Ágh T, van Boven JF, Wettermark B, Menditto E, Pinnock H, Tsiligianni I, Petrova G, Potočnjak I, Kamberi F, Kardas P.
PMID: 34163364
Front Pharmacol. 2021 Jun 07;12:685696. doi: 10.3389/fphar.2021.685696. eCollection 2021.

Maintaining healthcare for noncommunicable diseases (NCDs) is particularly important during the COVID-19 pandemic; however, diversion of resources to acute care, and physical distancing restrictions markedly affected management of NCDs. We aimed to assess the medication management practices in place...

Cite
Ágh T, van Boven JF, Wettermark B, et al. A Cross-Sectional Survey on Medication Management Practices for Noncommunicable Diseases in Europe During the Second Wave of the COVID-19 Pandemic. Front Pharmacol. 2021;12:685696doi: 10.3389/fphar.2021.685696.
Ágh, T., van Boven, J. F., Wettermark, B., Menditto, E., Pinnock, H., Tsiligianni, I., Petrova, G., Potočnjak, I., Kamberi, F., & Kardas, P. (2021). A Cross-Sectional Survey on Medication Management Practices for Noncommunicable Diseases in Europe During the Second Wave of the COVID-19 Pandemic. Frontiers in pharmacology, 12685696. https://doi.org/10.3389/fphar.2021.685696
Ágh, Tamás, et al. "A Cross-Sectional Survey on Medication Management Practices for Noncommunicable Diseases in Europe During the Second Wave of the COVID-19 Pandemic." Frontiers in pharmacology vol. 12 (2021): 685696. doi: https://doi.org/10.3389/fphar.2021.685696
Ágh T, van Boven JF, Wettermark B, Menditto E, Pinnock H, Tsiligianni I, Petrova G, Potočnjak I, Kamberi F, Kardas P. A Cross-Sectional Survey on Medication Management Practices for Noncommunicable Diseases in Europe During the Second Wave of the COVID-19 Pandemic. Front Pharmacol. 2021 Jun 07;12:685696. doi: 10.3389/fphar.2021.685696. eCollection 2021. PMID: 34163364; PMCID: PMC8216671.
Copy Download .nbib Format: NLM
Author Correction: Acute Heart Failure developed as worsening of Chronic Heart Failure is associated with increased mortality compared to de novo cases.

Scientific reports

Degoricija V, Trbušić M, Potočnjak I, Radulović B, Terešak SD, Pregartner G, Berghold A, Tiran B, Frank S.
PMID: 31165742
Sci Rep. 2019 Jun 05;9(1):8403. doi: 10.1038/s41598-019-44069-7.

A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.

Cite
Degoricija V, Trbušić M, Potočnjak I, et al. Author Correction: Acute Heart Failure developed as worsening of Chronic Heart Failure is associated with increased mortality compared to de novo cases. Sci Rep. 2019;9(1):8403doi: 10.1038/s41598-019-44069-7.
Degoricija, V., Trbušić, M., Potočnjak, I., Radulović, B., Terešak, S. D., Pregartner, G., Berghold, A., Tiran, B., & Frank, S. (2019). Author Correction: Acute Heart Failure developed as worsening of Chronic Heart Failure is associated with increased mortality compared to de novo cases. Scientific reports, 9(1), 8403. https://doi.org/10.1038/s41598-019-44069-7
Degoricija, Vesna, et al. "Author Correction: Acute Heart Failure developed as worsening of Chronic Heart Failure is associated with increased mortality compared to de novo cases." Scientific reports vol. 9,1 (2019): 8403. doi: https://doi.org/10.1038/s41598-019-44069-7
Degoricija V, Trbušić M, Potočnjak I, Radulović B, Terešak SD, Pregartner G, Berghold A, Tiran B, Frank S. Author Correction: Acute Heart Failure developed as worsening of Chronic Heart Failure is associated with increased mortality compared to de novo cases. Sci Rep. 2019 Jun 05;9(1):8403. doi: 10.1038/s41598-019-44069-7. PMID: 31165742; PMCID: PMC6549248.
Copy Download .nbib Format: NLM
Showing 1 to 8 of 8 entries